

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: MAILLIET et al. Examiner: JARRELL, Noble E.
Application No.: 10/658,394 Art Unit: 1609
Filed: September 10, 2003
Title: CHEMICAL DERIVATIVES AND THEIR APPLICATION AS
 ANTITELOMERASE AGENTS

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

Listed reference DE 198 12 879 A1 is in the German language. Canadian publication No. 2 325 489 is an English language family member of DE 198 12 879 A1, and is believed to have substantially similar content as DE 198 12 879 A1.

Listed references DE 199 35 219 A1 and WO01/07020 are in the German language. U.S. Patent No. 6,362,210 B1 is an English language family member of DE 199 35 219 A1 and WO01/07020, and is believed to have substantially similar content as DE 199 35 219 A1 and WO01/07020.

Listed reference JP 11-60573, Masayuki et al., is in the Japanese language. An English language abstract of JP 11-60573 is provided herewith.

Listed reference JP 53-47439, Shizuo et al., is in the Japanese language. An English language abstract of JP 53-47439 is provided herewith.

Listed reference JP 6-49062, Katsutoshi et al., is in the Japanese language. An English language abstract of JP 6-49062 is provided herewith.

Listed reference WO02/76975 is in the French language. U.S. Patent No. 6,887,873 is an English language family member of WO02/76975, and is believed to have substantially similar content as WO02/76975.

Listed reference WO02/096903 is in the French language. U.S. Patent No. 6,995,175 is an English language family member of WO02/096903, and is believed to have substantially similar content as WO02/096903.

Listed reference WO02/068408 is in the French language. U.S. Patent Application Publication No. US2003/0013711 is an English language family member of WO02/068408, and is believed to have substantially similar content as WO02/068408.

Listed reference WO0255515 is in the French language. U.S. Patent No. 6,858,608 is an English language family member of WO0255515, and is believed to have substantially similar content as WO0255515.

Listed reference WO2004/072027 is in the French language. Currently pending U.S. Patent Application No. 10/773,806 is an English language family member of WO2004/072027, and is believed to have substantially similar content as WO2004/072027.

Listed reference Kreutzberger et al. is in the German language. An English language abstract of Kreutzberger et al. is provided herewith.

The Commissioner is authorized to charge any additional fees which may be required by this paper or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,

June 26, 2007

Date

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (610) 889-8995
Telefax (908) 231-2626

Kelly L. Bender

Kelly L. Bender, Reg. No. 52,610
Attorney/Agent for Applicant

Sanofi-Aventis Docket No. ST99049G1 US DIV

☒

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/658,394	
			Filing Date	09-26-2003	
			First Named Inventor	MAILLIET	
			Group Art Unit	1609	
			Examiner Name	JARRELL, Noble E.	
Sheet	1	of	4	Attorney Docket Number	ST99049G1 - US - DIV

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		CA	2 325 489		LEHR et al	09-30-1999		
		DE	198 12 879 A1		KIRSTEN et al	09-30-1999		
		DE	199 35 219 A1		HAUEL et al	02-01-2001		
		JP	11-60573		MASAYUKI et al	03-02-1999		
		JP	53-47439		SHIZUO et al	04-27-1978		
		JP	6-49062		KATSUTOSHI et al	02-22-1994		
		WO	01/07020 A2		HAUEL et al	02-01-2001		
		WO	01/19825 A1		DENNY et al	03-22-2001		
		WO	01/47897 A1		MORIARTY et al	07-05-2001		
		WO	93/20056		JARMAN et al	10-14-1993		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

☒

+

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/658,394	
			Filing Date	09-26-2003	
			First Named Inventor	MAILLIET	
			Group Art Unit	1609	
			Examiner Name	JARRELL, Noble E.	
			Attorney Docket Number	ST99049G1 - US - DIV	
Sheet	2	of	4		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/658,394
		Filing Date	09-26-2003
		First Named Inventor	MAILLIET
		Group Art Unit	1609
		Examiner Name	JARRELL, Noble E.
Attorney Docket Number	ST99049G1 - US - DIV		
Sheet	3	of	4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ATWELL et al, Potential Antitumor Agents. V. Bisquaternary Salts, J. Med. Chem., Vol. 10, July 1967, pp. 706-713	
		ATWELL et al, Potential Antitumor Agents. VI. Bisquaternary Salts, J. Med. Chem., Vol.11, March 1968, pp. 295-300	
		CAIN et al, Potential Antitumor Agents. X. Bisquaternary Salts, J. Med. Chem., Vol. 12, No. 2, March 1969, pp. 199-206	
		CHEN et al, Spectroscopic Recognition of Guanine Dimeric Hairpin Quadruplexes by a Carbocyanine Dye, Proc. Natl. Acad. Sci. USA, Vol. 93, pp.2635-2639, April 1996	
		DENNY et al, Potential Antitumor Agents, 29. Quantitative Structure-Activity Relationships for the Antileukemic Bisquaternary Ammonium Heterocycles, J. Med. Chem., 1979, Vol. 22, No. 2, pp. 134-150	
		HIRATANI et al, 2,6-Bis[N-(8-quinolyl)carbamoyl]pyridine as a Highly Selective Extractant for Cu(II), Bulletin of The Chemical Society of Japan, 1990, 63, pp. 3331-3333	
		KATSUTOSHI et al, Pyrimidinylamino-or Triazinylaminoquinoline Derivative and Its Production and Agricultural and Horticultural Germicide Containing the Same as Active Ingredient, Patent Abstracts of Japan, Publication No. 06049062 A, Publication Date Feb. 22, 1994	
		KITTLER et al, Sequence Specific Modulation on DNA Restriction Enzyme Cleavage By Minor Groove Binders, Biol. Chem., Vol. 379, pp. 519-525, April/May 1998	
		KREUTZBERGER et al, Synthesis And Spectroscopic Analyses Of Dianilinotriazines, English Language Abstract of Chemiker-Zeitung (1990, pp.208-210, volume 114)	
		KREUTZBERGER, ET AL, Synthesis And Spectroscopic Analyses Of Dianilinotriazines, Chemiker-Zeitung (1990, pp.208-210, volume 114)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/658,394		
		Filing Date	09-26-2003		
		First Named Inventor	MAILLIET		
		Group Art Unit	1609		
		Examiner Name	JARRELL, Noble E.		
Sheet	4	of	4	Attorney Docket Number	ST99049G1 - US - DIV

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MASAYUKI et al, Triazine Derivative and Telomerase Inhibitor, English Language Abstract of JP11-60573	
		MOKBEL et al, Telomerase and Breast Cancer: From Diagnosis to Therapy, Abstract of Int. J. Sug. Investig. 2000, 2(1), pp. 85-88	
		PANDYA et al, Studies on Potential Drugs : Potential Anthelmintics Part I, J. Inst. Chemists (India), Vol. XLVII, November 1975 pp. 235-237	
		SHIZUO et al, Coloring of High Molecular Weight Material, English Language Abstract of JP 53-47439	
		SUN et al, Inhibition of Human Telomerase by a G-Quadruplex-Interactive Compound, J. Med. Chem., 1997, 40, pp. 2113-2116	
		SWELLAM et al, Emerging role of p53, bcl-2 and Telomerase Activity in Egyptian Breast Cancer Patients, Abstract of IUBMB Life, 2004, 56(8), 483-490	
		WHEELHOUSE et al, Cationic Porphyrins as Telomerase Inhibitors: the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA, J. Am. Chem. Soc., 1998, 120, pp. 3261-3262	
		WHITTEN et al, Rapid Microscale Synthesis, a New method for Lead Optimization Using Robotics and Solution Phase Chemistry: Application to the Synthesis and Optimization of Corticotropin-Releasing Factor1 Receptor Antagonists, J. Med. Chem., 1996, 39, pp. 4354-4357	
		Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, Volume 1, 1004-1010, 1996	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.